About Ascentage Pharma
Ascentage Pharma is a company based in Hong Kong (China) founded in 2009.. Ascentage Pharma has raised $237.5 million across 3 funding rounds from investors including ArrowMark Partners, CTS Capital Advisors and Oriza Ventures. Ascentage Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Hong Kong, China
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$237.5 M (USD)
in 3 rounds
-
Latest Funding Round
$150 M (USD), Series C
Jul 17, 2018
-
Investors
ArrowMark Partners
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
23 people
Operations Team
7 people
Clinical Team
5 people
Scientific Team
3 people
Data Analysis and Operations Team
3 people
Legal and Compliance
2 people
Senior Team
2 people
Product Management Team
2 people
Unlock access to complete
Funding Insights of Ascentage Pharma
Ascentage Pharma has successfully raised a total of $237.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $150 million completed in July 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $150.0M
-
First Round
First Round
(15 Aug 2015)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2018 | Amount | Series C - Ascentage Pharma | Valuation | Oriza Ventures , Yuan Ming Capital | |
| Dec, 2016 | Amount | Series B - Ascentage Pharma | Valuation | SDIC Innovation | |
| Aug, 2015 | Amount | Series A - Ascentage Pharma | Valuation | Oriza Ventures , Yuan Ming Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ascentage Pharma
Ascentage Pharma has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include ArrowMark Partners, CTS Capital Advisors and Oriza Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
PE firm focused on medicine based companies
|
Founded Year | Domain | Location | |
|
Private equity firm investing in multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ascentage Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ascentage Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ascentage Pharma Comparisons
Competitors of Ascentage Pharma
Ascentage Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ascentage Pharma
Frequently Asked Questions about Ascentage Pharma
When was Ascentage Pharma founded?
Ascentage Pharma was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Where is Ascentage Pharma located?
Ascentage Pharma is headquartered in Hong Kong, China.
Is Ascentage Pharma a funded company?
Ascentage Pharma is a funded company, having raised a total of $237.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $15.5M, raised on Aug 15, 2015.
What does Ascentage Pharma do?
Ascentage Pharma was founded in 2009 in Hong Kong, China, where small molecule drugs targeting cancers are developed. The pipeline includes AT101 as a pan-Bcl-2 inhibitor for non-small cell lung cancer, HQP8361 as a c-Met inhibitor for solid tumors, APG-1387 as an IAP inhibitor for solid tumors, and HQP1351 as a Bcr-Abl kinase inhibitor for chronic myeloid leukemia. Key oncogenic drivers in human cancers are addressed by several preclinical programs.
Who are the top competitors of Ascentage Pharma?
Ascentage Pharma's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Ascentage Pharma's investors?
Ascentage Pharma has 11 investors. Key investors include ArrowMark Partners, CTS Capital Advisors, Oriza Ventures, CCB International, and Yuan Ming Capital.